Q-omics provides the consensus-scored DOCK11 profile across patient tissues and cancer cell-line models. DOCK11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DOCK11 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DOCK11 protein abundance shows 26,598 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where DOCK11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOCK11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOCK11 survival associations across molecular data types. DOCK11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOCK11 RNA expression–survival associations across cancer types. High DOCK11 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, HNSC, SCLC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for DOCK11 RNA expression.
This table summarizes DOCK11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DOCK11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOCK11 shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in HNSC and KIRP. The HNSC box plot shows higher DOCK11 RNA expression in tumor versus normal tissue (log2 FC = +1.888, t-test p < 0.001).
This table shows molecular features associated with DOCK11 in patient tissues and cancer cell lines. In patient samples, DOCK11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DOCK11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
